Form 4: aTyr Pharma CEO Reports RSU Vesting, Tax-Related Stock Sale

aTyr Pharma's President and CEO, Sanjay Shukla, reported the vesting of 10,375 restricted stock units and a subsequent sale of 3,745 shares to cover tax obligations.

Summary

• Sanjay Shukla, President and CEO of aTyr Pharma Inc., acquired 10,375 shares of common stock on February 3, 2026, through the vesting of restricted stock units (RSUs).
• These RSUs were originally granted on February 3, 2022, and convert into common stock on a one-for-one basis.
• On February 4, 2026, Mr. Shukla sold 3,745 shares of common stock at a price of $0.976 per share.
• This sale was conducted to satisfy tax withholding obligations associated with the partial vesting of the RSUs.
• Following these transactions, Mr. Shukla directly beneficially owns 153,553 shares of aTyr Pharma common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine execution of an executive compensation plan and continued alignment of the CEO's interests with shareholders through RSU vesting.

Positives

• The vesting of 10,375 restricted stock units indicates continued long-term incentive alignment between the CEO and shareholders.
• The RSU grant structure includes accelerated vesting provisions under certain conditions, such as termination without cause upon a change of control, which can be beneficial for executive retention.

Negatives

• The sale of 3,745 shares, although for tax purposes, reduces the CEO's direct beneficial ownership in the company.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as those related to RSU vesting and subsequent tax-related sales, are common across the biotechnology and pharmaceutical industries. These transactions typically reflect pre-planned compensation structures rather than a change in management's outlook on the company's prospects.

Related Party Transactions

• The acquisition of 10,375 shares resulted from the vesting of Restricted Stock Units (RSUs) granted to Sanjay Shukla, the President and CEO, as part of his compensation package.

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns management's interests with shareholders, while the tax-related sale is a routine event with minimal direct impact on company operations or strategy.

Next Steps

• The remaining RSUs from the February 3, 2022 grant are scheduled to fully vest on February 3, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving RSU vesting and a tax-related sale, which does not provide new fundamental information to warrant a change in investment recommendation. The transaction reflects standard executive compensation practices and does not indicate a shift in the company's operational or financial outlook. Investors should continue to hold based on broader company fundamentals rather than this specific filing.

Keywords

aTyr Pharma, ATYR, Sanjay Shukla, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, CEO